Finance

Lists
Why is GUTS up 11,27%?
Dive Deeper
GUTS:NASDAQ
Fractyl Health Inc
0,90 USD
+11,27%
(+0,091) 1D
13-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GUTS...
Open
0,85 USD
High
0,95 USD
Low
0,84 USD
Mkt. cap
11,99 млн
Avg. vol.
856,85 миң
Volume
424,36 миң
52-wk high
29,34 USD
52-wk low
0,80 USD
EPS
-13,43 USD
Shares outstanding
13,26 млн
No. of employees
100
Open
0,85 USD
High
0,95 USD
Low
0,84 USD
Mkt. cap
11,99 млн
Avg. vol.
856,85 миң
Volume
424,36 миң
52-wk high
29,34 USD
52-wk low
0,80 USD
EPS
-13,43 USD
Shares outstanding
13,26 млн
No. of employees
100
News stories
From web sources and news partners
Profile
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
About Fractyl Health Inc
CEO-
Employees100
Founded2010
HeadquartersБерлингтон, Массачусетс, Америка Кошмо Штаттары
SectorHealth Care
IndustryMedical device
Websitefractyl.com
Analyst ratings
Based on 5 analysts giving stock ratings to GUTS in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for GUTS in the last 3 months.
Highest
Current 0,90 USD
40,00 USD (+4 326,74%)
Average
18,00 USD (+1 892,03%)
Lowest
4,00 USD (+342,67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/13/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
4,00 USD
+342,7%
11/13/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
24,00 USD
+2 556%
11/13/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
40,00 USD
+4 326,7%
11/13/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
4,00 USD
+342,7%
10/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
17,46 млн
16,49 млн
15,60 млн
13,81 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,24 млн
6,79 млн
5,22 млн
5,28 млн
Operating expense
22,69 млн
23,28 млн
20,82 млн
19,10 млн
Total operating expenses
22,69 млн
23,28 млн
20,82 млн
19,10 млн
Operating income
-22,69 млн
-23,28 млн
-20,82 млн
-19,10 млн
Other non operating income
-21,21 млн
-20,19 млн
30,06 млн
-5,49 млн
EBT including unusual items
-45,60 млн
-43,73 млн
9,22 млн
-25,54 млн
EBT excluding unusual items
-43,74 млн
-42,83 млн
9,83 млн
-24,16 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-45,60 млн
-43,73 млн
9,22 млн
-25,54 млн
Net profit margin
-
-
-
-
Earnings per share
-8,52
-0,84
-1,53
-1,41
Interest and investment income
166,00 миң
645,00 миң
593,00 миң
431,00 миң
Interest expense
-
-
-
-
Net interest expenses
166,00 миң
645,00 миң
593,00 миң
431,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,40 млн
-23,00 млн
-20,54 млн
-18,82 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору